Pamidronate Treatment of Osteonecrosis of the Hip in Young Male

BACKGROUND: Aseptic osteonecrosis of the hip is a clinical entity in which the necrotic process of the bone leads to pain and progressive disability. OBJECTIVE: Pamidronate seems to reduce drastically the activation of the osteoclasts so that it can be useful only in the early stage of the disease,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo Gullo, A., Talotta, R., Atteritano, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2018
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118033/
https://www.ncbi.nlm.nih.gov/pubmed/30197706
http://dx.doi.org/10.2174/1874312901812010125
Descripción
Sumario:BACKGROUND: Aseptic osteonecrosis of the hip is a clinical entity in which the necrotic process of the bone leads to pain and progressive disability. OBJECTIVE: Pamidronate seems to reduce drastically the activation of the osteoclasts so that it can be useful only in the early stage of the disease, delaying the time of bone collapsing. METHOD: A 27-years-old male was treated with pamidronate for three consecutive days every four weeks. RESULTS: After three months the patient came back at control showing a marked improvement in clinical condition, referred full recover from pain and dysmotility with improvement of the quality of life, which was confirmed by the result of MRI he had for control. CONCLUSION: We reported a case of aseptic osteonecrosis of the hip which was successfully treated pamidronate at dosage of 45 mg.

Ejemplares similares